While Luminal A, Luminal B, and HER2‐positive subtypes of breast cancer typically exhibit favorable treatment outcomes, significant challenges persist concerning mortality rates, recurrence, and treatment‐related adverse effects, particularly in TNBC, which is characterized by limited therapeutic options and poorer prognoses. This evidence concerns the gene ERBB2 and breast carcinoma.